Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer.
about
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?Safety and effectiveness of localized lung resection combined with neoadjuvant chemotherapy in the treatment of stage I-II non-small cell lung cancer.Current state of immunotherapy for non-small cell lung cancer.Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy.Programmed death-ligand 1 expression in rectal cancer.Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions.Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma.The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors.Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer.Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab.Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients.Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and reviewMetabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on 18 F-fluorodeoxyglucose positron emission tomography/computed tomography.Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization.Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.Role of immune-checkpoint inhibitors in lung cancer.A correlative analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 expression in oropharyngeal squamous cell carcinoma.Expression patterns of programmed death-ligand 1 in esophageal adenocarcinomas: comparison between primary tumors and metastases.YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting.Personalized medicine in immuno-oncology: a novel prognostic index in non-small cell lung cancer.Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma.Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects
P2860
Q26741101-B46BF7A8-17EB-4886-ABCE-7F25CCF4AD8AQ33598542-63BAB19C-935F-4435-88CB-412538F55FD9Q33645595-FF56A392-53E8-4BB2-BADC-6D4204A16575Q37308194-8D2A80BF-59E9-46A0-87F6-49F309DB85C8Q37515182-C23A5B9D-6668-46B3-B951-9BCBA9EFD88DQ37665660-682EFC01-7F5C-4B1B-A08F-CD4E76E4E0D7Q37702705-BB6F2654-C14B-43D9-BDFC-BA724CF10A9AQ38401891-65D936CB-597A-4167-AEB9-558955F72DB4Q38604723-36A12FE2-CF14-4865-814F-5AFA9AC34620Q38796541-56AE351B-06A5-4D81-9C15-80FA8B1134D5Q39470931-C0F3D90B-162E-4D97-AFF6-A394459C9953Q41201725-C63EB737-8D2B-4A35-AACE-9C4A67487204Q41613025-6E590580-EBB7-4E94-9BA2-088C1917E7BCQ44508044-3E5EAE0D-EB40-4D3E-8117-67B64DAB266BQ46178018-BECF3681-BC4C-44A7-A1B4-742A40175A37Q47164059-8D40911B-5874-4960-8A2E-684DB19A36BEQ47621538-EB170863-78D3-4ADD-912A-A189EBA7714CQ49549096-BF582BBE-A4FA-48A6-BD21-BF49E3C2F352Q50027076-83E47828-C60B-4EDE-9C59-846D43EB12C8Q51099991-40D35BE1-484C-45B3-8AEF-4E81F646F7A2Q53686708-875C79C2-90BA-42F9-9D01-0A9BFB14CD7EQ55098219-ED5DAEF0-ABAB-49C1-B677-244AF6F4C5A1Q55224585-A44725AB-FA4B-4ECE-9807-76C83F63A33DQ57174881-44ED3D52-6026-484D-A7FB-1FE2399AF5AA
P2860
Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Expression of programmed death ...... in non-small cell lung cancer.
@ast
Expression of programmed death ...... in non-small cell lung cancer.
@en
type
label
Expression of programmed death ...... in non-small cell lung cancer.
@ast
Expression of programmed death ...... in non-small cell lung cancer.
@en
prefLabel
Expression of programmed death ...... in non-small cell lung cancer.
@ast
Expression of programmed death ...... in non-small cell lung cancer.
@en
P2093
P2860
P356
P1433
P1476
Expression of programmed death ...... in non-small cell lung cancer.
@en
P2093
Hongyun Zhao
Jianhua Zhan
Wenfeng Fang
Yunpeng Yang
Yuxiang Ma
P2860
P2888
P356
10.1038/SREP20090
P407
P577
2016-01-29T00:00:00Z